| Diagnosis and treatment of malignant pleural effusion: a systematic literature review and new approaches G Lombardi, F Zustovich, MO Nicoletto, M Donach, G Artioli, D Pastorelli American Journal of Clinical Oncology 33 (4), 420-423, 2010 | 121 | 2010 |
| Sorafenib plus daily low-dose temozolomide for relapsed glioblastoma: a phase II study F Zustovich, L Landi, G Lombardi, C Porta, L Galli, A Fontana, D Amoroso, ... Anticancer research 33 (8), 3487-3494, 2013 | 116 | 2013 |
| Sequential use of sorafenib and sunitinib in advanced renal‐cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases C Porta, G Procopio, G Cartenì, R Sabbatini, A Bearz, I Chiappino, ... BJU international 108 (8b), E250-E257, 2011 | 115 | 2011 |
| Clinical outcomes of castration-resistant prostate cancer treatments administered as third or fourth line following failure of docetaxel and other second-line treatment … O Caffo, U De Giorgi, L Fratino, D Alesini, V Zagonel, G Facchini, ... European urology 68 (1), 147-153, 2015 | 101 | 2015 |
| Pegylated liposomal doxorubicin and gemcitabine in patients with advanced hepatocellular carcinoma: results of a phase 2 study G Lombardi, F Zustovich, F Farinati, U Cillo, A Vitale, G Zanus, M Donach, ... Cancer 117 (1), 125-133, 2011 | 71 | 2011 |
| Clinical and genetic factors associated with severe hematological toxicity in glioblastoma patients during radiation plus temozolomide treatment: a prospective study G Lombardi, E Rumiato, R Bertorelle, D Saggioro, P Farina, ... American journal of clinical oncology 38 (5), 514-519, 2015 | 69 | 2015 |
| A validated prognostic classifier for V600EBRAF-mutated metastatic colorectal cancer: the ‘BRAF BeCool’study F Loupakis, R Intini, C Cremolini, A Orlandi, A Sartore-Bianchi, ... European Journal of Cancer 118, 121-130, 2019 | 66 | 2019 |
| First-line PAzopanib in NOn–clear-cell renal cArcinoMA: The Italian retrospective multicenter PANORAMA study S Buti, M Bersanelli, F Maines, G Facchini, F Gelsomino, F Zustovich, ... Clinical genitourinary cancer 15 (4), e609-e614, 2017 | 60 | 2017 |
| Metastatic oligodendrogliomas: a review of the literature and case report F Zustovich, A Della Puppa, R Scienza, P Anselmi, C Furlan, G Cartei Acta neurochirurgica 150, 699-703, 2008 | 52 | 2008 |
| A phase II study of cisplatin and temozolomide in heavily pre-treated patients with temozolomide-refractory high-grade malignant glioma F Zustovich, G Lombardi, A Della Puppa, A Rotilio, R Scienza, D Pastorelli Anticancer research 29 (10), 4275-4279, 2009 | 50 | 2009 |
| Cardiac metastasis from renal cell carcinoma without inferior vena involvement: a review of the literature based on a case report. Two different patterns of spread? F Zustovich, F Gottardo, L De Zorzi, A Cecchetto, M Dal Bianco, E Mauro, ... International journal of clinical oncology 13, 271-274, 2008 | 47 | 2008 |
| Docetaxel, with or without estramustine phosphate, as first‐line chemotherapy for hormone‐refractory prostate cancer: results of a multicentre, randomized phase II trial O Caffo, T Sava, E Comploj, A Fariello, F Zustovich, R Segati, C Sacco, ... BJU international 102 (9), 1080-1085, 2008 | 45 | 2008 |
| Neoplastic meningitis from solid tumors: new diagnostic and therapeutic approaches G Lombardi, F Zustovich, P Farina, A Della Puppa, R Manara, D Cecchin, ... The oncologist 16 (8), 1175-1188, 2011 | 44 | 2011 |
| Hypertension as a biomarker in patients with recurrent glioblastoma treated with antiangiogenic drugs: a single-center experience and a critical review of the literature G Lombardi, F Zustovich, P Farina, P Fiduccia, A Della Puppa, V Polo, ... Anti-cancer drugs 24 (1), 90-97, 2013 | 40 | 2013 |
| Safety and efficacy of cabozantinib in metastatic renal-cell carcinoma: real-world data from an Italian managed access program G Procopio, M Prisciandaro, R Iacovelli, E Cortesi, G Fornarini, G Facchini, ... Clinical Genitourinary Cancer 16 (4), e945-e951, 2018 | 38 | 2018 |
| Cabozantinib after a previous immune checkpoint inhibitor in metastatic renal cell carcinoma: a retrospective multi-institutional analysis R Iacovelli, C Ciccarese, G Facchini, M Milella, F Urbano, U Basso, ... Targeted Oncology 15, 495-501, 2020 | 36 | 2020 |
| First-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS-BRAF wild-type metastatic colorectal cancer elderly patients: The PANDA study. S Lonardi, M Schirripa, F Buggin, L Antonuzzo, B Merelli, G Boscolo, ... Journal of Clinical Oncology 38 (15_suppl), 4002-4002, 2020 | 36 | 2020 |
| Targeted α therapies for the treatment of bone metastases F Zustovich, R Barsanti International journal of molecular sciences 19 (1), 74, 2017 | 35 | 2017 |
| Bevacizumab-based therapy for patients with brain metastases from non-small-cell lung cancer: preliminary results F Zustovich, A Ferro, G Lombardi, P Farina, V Zagonel Chemotherapy 60 (5-6), 294-299, 2015 | 35 | 2015 |
| Bevacizumab as front-line treatment of brain metastases from solid tumors: a case series F Zustovich, A Ferro, G Lombardi, V Zagonel, P Fiduccia, P Farina Anticancer Research 33 (9), 4061-4065, 2013 | 33 | 2013 |
